Investor Presentaiton

SELECT TRIALS - TIRZEPATIDE Study Indication* Title Phase Patients Primary Outcome* ** Lilly Primary Completion Completion NCT04184622 Obesity A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) 3 2539 Percent Change from Baseline in Body Weight Apr 2022 Jul 2024 A Study of Tirzepatide (LY3298176) in Participants With NCT05822830 Obesity Obesity or Overweight With Weight Related Comorbidities NCT05556512 Obesity (SURMOUNT-5) A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) 3 700 Percent Change from Baseline in Body Weight Nov 2024 Dec 2024 3 15000 Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events) Oct 2027 Oct 2027 NCT04255433 Type 2 Diabetes A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT) 3 13299 Time to First Occurrence of Death from Cardiovascular [CV] Causes, Myocardial Infarction (MI), or Stroke (MACE- 3) Oct 2024 Oct 2024 NCT05260021 Type 2 Diabetes A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS) 3 90 Change From Baseline in Hemoglobin A1c (HbA1c) Nov 2027 Dec 2027 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, July 14, 2023 2023 Q2 EARNINGS 48

View entire presentation